JP2020503017A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020503017A5 JP2020503017A5 JP2019533110A JP2019533110A JP2020503017A5 JP 2020503017 A5 JP2020503017 A5 JP 2020503017A5 JP 2019533110 A JP2019533110 A JP 2019533110A JP 2019533110 A JP2019533110 A JP 2019533110A JP 2020503017 A5 JP2020503017 A5 JP 2020503017A5
- Authority
- JP
- Japan
- Prior art keywords
- modified
- compound according
- nucleoside
- crrna
- modified crrna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002777 nucleoside Substances 0.000 claims 23
- 150000001875 compounds Chemical class 0.000 claims 22
- 125000003835 nucleoside group Chemical group 0.000 claims 12
- 101710163270 Nuclease Proteins 0.000 claims 5
- -1 linker nucleoside compound Chemical class 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 4
- 108091033409 CRISPR Proteins 0.000 claims 3
- 238000010354 CRISPR gene editing Methods 0.000 claims 3
- 238000012986 modification Methods 0.000 claims 3
- 230000004048 modification Effects 0.000 claims 3
- YIMATHOGWXZHFX-WCTZXXKLSA-N (2r,3r,4r,5r)-5-(hydroxymethyl)-3-(2-methoxyethoxy)oxolane-2,4-diol Chemical compound COCCO[C@H]1[C@H](O)O[C@H](CO)[C@H]1O YIMATHOGWXZHFX-WCTZXXKLSA-N 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000013612 plasmid Substances 0.000 claims 2
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662439828P | 2016-12-28 | 2016-12-28 | |
| US62/439,828 | 2016-12-28 | ||
| US201762491818P | 2017-04-28 | 2017-04-28 | |
| US62/491,818 | 2017-04-28 | ||
| US201762572361P | 2017-10-13 | 2017-10-13 | |
| US62/572,361 | 2017-10-13 | ||
| PCT/US2017/068642 WO2018125964A1 (en) | 2016-12-28 | 2017-12-28 | Modified crispr rna and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020503017A JP2020503017A (ja) | 2020-01-30 |
| JP2020503017A5 true JP2020503017A5 (OSRAM) | 2021-02-12 |
Family
ID=62710685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019533110A Pending JP2020503017A (ja) | 2016-12-28 | 2017-12-28 | 修飾ｃｒｉｓｐｒ ｒｎａ及びその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20190382751A1 (OSRAM) |
| EP (1) | EP3562942A4 (OSRAM) |
| JP (1) | JP2020503017A (OSRAM) |
| AU (1) | AU2017388379A1 (OSRAM) |
| CA (1) | CA3047330A1 (OSRAM) |
| WO (1) | WO2018125964A1 (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3652312A1 (en) | 2017-07-14 | 2020-05-20 | Editas Medicine, Inc. | Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites |
| AU2019291918B2 (en) | 2018-06-29 | 2025-06-12 | Editas Medicine, Inc. | Synthetic guide molecules, compositions and methods relating thereto |
| AU2020291467A1 (en) * | 2019-06-14 | 2021-12-23 | Arbor Biotechnologies, Inc. | Novel crispr DNA targeting enzymes and systems |
| WO2022086846A2 (en) * | 2020-10-19 | 2022-04-28 | Caribou Biosciences, Inc. | Dna-containing polynucleotides and guides for crispr type v systems, and methods of making and using the same |
| US20250325698A1 (en) * | 2022-04-13 | 2025-10-23 | Caribou Biosciences, Inc. | Therapeutic applications of crispr type v systems |
| AU2024270764A1 (en) | 2023-05-15 | 2025-12-04 | Nchroma Bio, Inc. | Compositions and methods for epigenetic regulation of hbv gene expression |
| CN116732075B (zh) * | 2023-06-09 | 2024-03-08 | 江南大学 | 一种生产2′-岩藻糖基乳糖的多层动态调控系统及其应用 |
| WO2025212120A1 (en) * | 2024-04-05 | 2025-10-09 | Arbor Biotechnologies, Inc. | Chemical modifications of guide rnas for crispr nucleases |
| WO2025231432A1 (en) * | 2024-05-03 | 2025-11-06 | Caribou Biosciences, Inc. | In vivo gene editing with crispr systems |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9885033B2 (en) * | 2013-03-15 | 2018-02-06 | The General Hospital Corporation | Increasing specificity for RNA-guided genome editing |
| US20150376587A1 (en) * | 2014-06-25 | 2015-12-31 | Caribou Biosciences, Inc. | RNA Modification to Engineer Cas9 Activity |
| CN107250148B (zh) * | 2014-12-03 | 2021-04-16 | 安捷伦科技有限公司 | 具有化学修饰的指导rna |
| SG10201804715WA (en) * | 2015-01-28 | 2018-07-30 | Pioneer Hi Bred Int | Crispr hybrid dna/rna polynucleotides and methods of use |
| US9790490B2 (en) * | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
| EP3313989B1 (en) * | 2015-06-29 | 2024-12-25 | Ionis Pharmaceuticals, Inc. | Modified crispr rna and modified single crispr rna and uses thereof |
| WO2017181107A2 (en) * | 2016-04-16 | 2017-10-19 | Ohio State Innovation Foundation | Modified cpf1 mrna, modified guide rna, and uses thereof |
| CN106244591A (zh) * | 2016-08-23 | 2016-12-21 | 苏州吉玛基因股份有限公司 | 修饰crRNA在CRISPR/Cpf1基因编辑系统中的应用 |
| JP2019535287A (ja) * | 2016-11-22 | 2019-12-12 | インテグレイテツド・デイー・エヌ・エイ・テクノロジーズ・インコーポレイテツド | Ｃｒｉｓｐｒ／ｃｐｆ１システム及び方法 |
-
2017
- 2017-12-28 EP EP17886910.3A patent/EP3562942A4/en not_active Withdrawn
- 2017-12-28 US US16/470,464 patent/US20190382751A1/en not_active Abandoned
- 2017-12-28 AU AU2017388379A patent/AU2017388379A1/en not_active Abandoned
- 2017-12-28 CA CA3047330A patent/CA3047330A1/en not_active Abandoned
- 2017-12-28 WO PCT/US2017/068642 patent/WO2018125964A1/en not_active Ceased
- 2017-12-28 JP JP2019533110A patent/JP2020503017A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020503017A5 (OSRAM) | ||
| JP2019506889A5 (OSRAM) | ||
| ES2858403T3 (es) | Acidos nucleicos de doble hebra modificados por ligando | |
| AU2017277918B2 (en) | High specificity genome editing using chemically modified guide RNAs | |
| JP2016116520A5 (OSRAM) | ||
| JP2019517268A5 (OSRAM) | ||
| JP2019511491A5 (OSRAM) | ||
| JP2016513976A5 (OSRAM) | ||
| WO2007134014A3 (en) | Compounds and methods for modulating expression of gcgr | |
| JP2016520312A5 (OSRAM) | ||
| JP2018510621A5 (OSRAM) | ||
| JP2020532961A5 (OSRAM) | ||
| RU2016123086A (ru) | Способы и композиции для лечения болезни хантингтона | |
| JP2020500929A5 (OSRAM) | ||
| JPWO2019237069A5 (OSRAM) | ||
| JP2007509040A5 (OSRAM) | ||
| CY1118963T1 (el) | Βιολογικα συστηματα μεταφορας πολλαπλου-συστατικου | |
| JP2013535212A5 (OSRAM) | ||
| WO2008116860A3 (en) | Dsrna compositions and methods for treating hpv infections | |
| JP2009532044A5 (OSRAM) | ||
| JP2017505623A5 (OSRAM) | ||
| EP1224280A2 (en) | Design of high affinity rnase h recruiting oligonucleotide | |
| JP2007505954A5 (OSRAM) | ||
| BRPI0717510A2 (pt) | Análogos de oligonucleotídeo cpg contendo análogos t hidrofóbicos com atividade imunoestimulatória intensificada | |
| JP2017523790A5 (OSRAM) |